HK Stock Market Move | INNOGEN-B (02591) rose by nearly 10% and will be included in the Hang Seng Composite Index starting from December 8th.

INNOGEN-B(02591) rose nearly 10%, and as of the time of the report, it rose by 9.81% to 31.8 Hong Kong dollars, with a turnover of 2.7693 million Hong Kong dollars. On the news front, on November 21st, the results of the quarterly review of the Hang Seng Index series were announced, and all changes will take effect starting from December 8, 2025. Among them, Hegen Pharmaceuticals was included in the Hang Seng Composite Index constituents. In September of this year, Hegen Pharmaceuticals announced that the company had administered the first patient in China for the Phase III clinical trial of its core product, exenatide , for the treatment of obesity and overweight. The company plans to recruit approximately 800 participants for this clinical trial. Shanghai Securities previously pointed out that exenatide of Hegen Pharmaceuticals has good safety and lowering blood sugar and weight-loss effects, showing significant advantages in the treatment of chronic metabolic diseases such as diabetes, obesity, and fatty liver. The company's listing on the Hong Kong Stock Exchange is expected to advance its research and development pipeline and commercial expansion. Interest in the GLP-1 field remains strong, competition continues to intensify, and it is recommended to pay attention to indications expansion, listing application, and commercialization progress.